Cambridge Heart Inc. (OTC:CAMH) enrolled the first participants in a clinical trial of its Microvolt T-Wave Alternans test for detecting ischemia, or restricted blood flow, in patients with coronary artery disease.
The 200-patient MTWA-CAD study is designed to determine whether the test can improve the diagnosis of ischemia. The test is currently used to predict whether patients are at risk for potentially fatal arrhythmias by measuring electrical signals in the heart, according to a press release.